Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Larochette N, Zamzami N, et al. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006;25: 4812–4830.
   PubMed Web of Science ®Google Scholar
• Fulda S. Exploiting mitochondrial apoptosis for the treatment of cancer. Mitochondrion 2010;10:598–603.
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47–59.
   PubMed Web of Science ®Google Scholar
• Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479–489.
   PubMed Web of Science ®Google Scholar
• Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33–42.
   PubMed Web of Science ®Google Scholar
• Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006;7:988–994.
   PubMed Web of Science ®Google Scholar
• van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10: 389–399.
   PubMed Web of Science ®Google Scholar
• Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004;305:1471–1474.
   PubMed Web of Science ®Google Scholar
• Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008;27(Suppl. 1):S149–S157.
   PubMed Web of Science ®Google Scholar
• Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010;9:447–464.
   PubMed Web of Science ®Google Scholar
• Wohlleber D, Kashkar H, Gartner K, et al. TNF-induced target cell killing by CTL activated through cross-presentation. Cell Rep 2012;2:478–487.
   PubMed Web of Science ®Google Scholar
• Bleackley RC. A molecular view of cytotoxic T lymphocyte induced killing. Biochem Cell Biol 2005;83:747–751.
   PubMed Web of Science ®Google Scholar
• Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010;17:616–623.
   PubMed Web of Science ®Google Scholar
• Bleackley RC, Heibein JA. Enzymatic control of apoptosis. Nat Prod Rep 2001;18:431–440.
   PubMed Web of Science ®Google Scholar
• Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000;192:1403–1414.
   PubMed Web of Science ®Google Scholar
• Heibein JA, Barry M, Motyka B, et al. Granzyme B-induced loss of mitochondrial inner membrane potential (Delta Psi m) and cytochrome c release are caspase independent. J Immunol 1999; 163:4683–4693.
   PubMed Web of Science ®Google Scholar
• Goping IS, Barry M, Liston P, et al. Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity 2003;18:355–365.
   PubMed Web of Science ®Google Scholar
• Sutton VR, Wowk ME, Cancilla M, et al. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 2003;18: 319–329.
   Google Scholar
• Kashkar H, Seeger JM, Hombach A, et al. XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 2006;108:3434–3440.
   PubMed Web of Science ®Google Scholar
• Ravi R, Fuchs EJ, Jain A, et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res 2006;66:1730–1739.
   PubMed Web of Science ®Google Scholar
• Seeger JM, Schmidt P, Brinkmann K, et al. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res 2010;70:1825–1834.
   PubMed Web of Science ®Google Scholar
• Kashkar H, Kronke M, Jurgensmeier JM. Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis. Cell Death Differ 2002;9:750–757.
   PubMed Web of Science ®Google Scholar
• Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682–693.
   PubMed Web of Science ®Google Scholar
• Kashkar H, Wiegmann K, Yazdanpanah B, et al. Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J Biol Chem 2005;280:20804–20813.
   PubMed Web of Science ®Google Scholar
• Kashkar H, Deggerich A, Seeger JM, et al. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 2007;109:3982–3988.
   PubMed Web of Science ®Google Scholar
• Brinkmann K, Zigrino P, Witt A, et al. Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep 2013;3:881–891.
   PubMed Web of Science ®Google Scholar
• Jost LM, Kirkwood JM, Whiteside TL. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 1992;147:153–165.
   PubMed Web of Science ®Google Scholar
• Granville DJ. Granzymes in disease: bench to bedside. Cell Death Differ 2010;17:565–566.
   PubMed Web of Science ®Google Scholar
• Durkop H, Hirsch B, Hahn C, et al. cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3. J Mol Med 2006;84:132–141.
   PubMed Web of Science ®Google Scholar
• Kashkar H, Haefs C, Shin H, et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003; 198:341–347.
   PubMed Web of Science ®Google Scholar
• Akyurek N, Ren Y, Rassidakis GZ, et al. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer 2006;107:1844–1851.
   PubMed Web of Science ®Google Scholar
• Muschen M, Re D, Brauninger A, et al. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res 2000;60:5640–5643.
   PubMed Web of Science ®Google Scholar
• Re D, Hofmann A, Wolf J, et al. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol 2000;28:31–35.
   PubMed Web of Science ®Google Scholar
• Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology 2011;58:15–25.
   PubMed Web of Science ®Google Scholar
• Ni Chonghaile T, Sarosiek KA, Vo TT, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011;334:1129–1133.
   PubMed Web of Science ®Google Scholar
• Jost PJ, Grabow S, Gray D, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009;460:1035–1039.
   PubMed Web of Science ®Google Scholar
• Maas C, Verbrugge I, de Vries E, et al. Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of type I tumor cells after TRAIL receptor stimulation. Cell Death Differ 2010;17:1613–1623.
   Google Scholar
• Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res 2010;16:4496–4502.
   PubMed Web of Science ®Google Scholar
• Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008;8:121–132.
   PubMed Web of Science ®Google Scholar
• Probst BL, Liu L, Ramesh V, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 2010;17:1645–1654.
   PubMed Web of Science ®Google Scholar
• Dineen SP, Roland CL, Greer R, et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010;70:2852–2861.
   Web of Science ®Google Scholar
• Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010;10:561–574.
   PubMed Web of Science ®Google Scholar
• Seeger JM, Brinkmann K, Yazdanpanah B, et al. Elevated XIAP expression alone does not confer chemoresistance. Br J Cancer 2010;102:1717–1723.
   PubMed Web of Science ®Google Scholar